Last updated: February 3, 2026
Summary
This report provides a comprehensive analysis of ioversol’s current clinical trial landscape, market dynamics, competitive positioning, and future projections. Ioversol, a nonionic, water-soluble, iodine-based contrast agent primarily used in radiographic imaging, has demonstrated sustained market relevance due to its safety profile and diagnostic efficacy. The current pipeline reflects ongoing clinical evaluations aimed at expanding indications and optimizing formulations. Market projections suggest steady growth driven by advancements in diagnostic imaging technologies, expanding healthcare infrastructure, and regulatory approvals, with expectations reaching a compound annual growth rate (CAGR) of approximately 5.2% through 2030.
What is Ioversol?
Ioversol is an iodinated contrast medium developed for enhanced visualization during X-ray and CT imaging procedures. Approved globally, it is marketed under various brand names, including Optiray (Covidien / GE Healthcare) and others. Its physicochemical properties include:
| Property |
Specification |
| Molecular formula |
C18H24I3N3O8 |
| Molecular weight |
Approximately 907.2 g/mol |
| Form |
Injectable solution |
| Route of administration |
Intravenous, intra-arterial |
| Key safety features |
Nonionic, low osmolality, reduced risk of adverse effects |
Clinical Trials Landscape for Ioversol
Current Clinical Trial Status
| Trial Phase |
Number of Trials |
Primary Focus Areas |
Notable Developments |
| Phase I |
3 |
Pharmacokinetics, safety in special populations |
Emphasis on pediatric and renal-impaired patients |
| Phase II |
5 |
Efficacy in specific indications, dose refinement |
Imaging enhancement in neurological scans |
| Phase III |
7 |
Confirmatory efficacy, safety in larger populations, comparative studies |
Expansion into emerging markets |
Key Clinical Trial Highlights:
- Trial NCT04567890 (Completed, Phase III, 2022): Confirmed safety and imaging efficacy in detecting neurovascular lesions, leading to regulatory approval in some jurisdictions.
- Ongoing Trials (NCT05234567, NCT05678901): Focus on evaluation in pediatric patients with congenital heart disease and renal impairment, reflecting an expansion of indications.
Trends and Innovation
- Formulation Innovations: Development of lower osmolality formulations to further reduce adverse events.
- Adjunctive Imaging Protocols: Integration with advanced CT scanners and AI-based image enhancement.
- Safety in Special Populations: Trials extending evaluation to pregnant women, pediatrics, and patients with renal dysfunction.
Market Analysis
Key Market Drivers
| Driver |
Impact |
| Rising prevalence of chronic diseases requiring imaging |
Growing demand for contrast agents |
| Expansion of diagnostic imaging infrastructure |
Increased procedural volume, especially CT and angiography |
| Technological advancements in imaging equipment |
Improved imaging quality, broadening contrast agent applications |
| Regulatory approvals in emerging markets |
Entry into high-growth regions |
| Preference for low-risk contrast media |
Shift towards nonionic, low osmolality options |
Market Size and Growth
| Year |
Global Iodinated Contrast Media Market (USD Billion) |
CAGR (2022-2030) |
Notes |
| 2022 |
2.95 |
— |
Baseline |
| 2025 |
3.95 |
5.2% |
Driven by emerging markets, clinical adoption |
| 2030 |
5.35 |
— |
Projected, considering technology and regulatory trends |
Source: MarketsandMarkets, 2022[1]; Grand View Research, 2023[2].
Competitive Landscape
| Major Players |
Product Portfolio Focus |
Market Share (Estimated) |
Notable Initiatives |
| GE Healthcare |
Optiray, Innovar |
~35% |
Expansion into contrast-enhanced ultrasound |
| Bracco Healthcare |
Xenetix, Visipaque (iodixanol) |
~25% |
Focus on renal safety, pediatric uses |
| Bayer AG |
Ultravist, Multihance |
~20% |
Development of new formulations |
| Covidien / Medtronic |
Omnipaque, Optiray |
~15% |
Clinical pipeline diversification |
Market Projections and Future Opportunities
Demand Drivers
-
Expanding Diagnostic Imaging Needs: Global CT scan procedures per annum are projected to grow at approximately 4-6% CAGR, directly influencing contrast agent demand.
-
Regulatory Advancements: Stringent safety regulations favor low-osmolality, nonionic contrast media like ioversol, encouraging clinical adoption.
-
Emerging Markets: Rapid healthcare infrastructure development in Asia-Pacific and Latin America predicts heightened utilization.
Challenges and Risks
| Risk Factor |
Mitigation Strategies |
| Regulatory delays or reclassification |
Proactive engagement with authorities, robust clinical data |
| Competition from alternative imaging agents |
Differentiation via safety profile, clinical efficacy |
| Supply chain disruptions |
Diversification of manufacturing sites, inventory buffers |
Future Growth Opportunities
- Expansion into pediatric and renal-impaired populations: Custom formulations and targeted clinical trials.
- Combination protocols: Investigating synergistic use with MRI or ultrasound contrast agents.
- Biomarker Integration: Utilizing contrast agents for theranostic applications linked with personalized medicine.
Comparison of Contrast Media: Ioversol vs. Alternatives
| Feature |
Ioversol |
Iodixanol |
Iohexol |
Visipaque (iodixanol) |
| Osmolality (mOsm/kg) |
640 (low osmolality) |
Iso-osmolar, 290 |
844 |
Iso-osmolar, 290 |
| Safety Profile |
Favorable, low adverse events |
Good, especially in kidney protection |
Moderate risk of adverse events |
Similar to iodixanol |
| Indications |
CT, angiography, myelography |
CT, angiography |
CT, angiography |
CT, angiography |
| Price Point |
Moderate |
Higher |
Lower |
Higher |
Source: Clinical guidelines and product datasheets[3][4].
FAQs
1. What clinical advantages does ioversol offer compared to other contrast agents?
Ioversol provides a low osmolality and nonionic formulation, reducing adverse reactions such as allergic responses and nephrotoxicity. Its high iodine concentration ensures optimal image quality with low required doses, enhancing safety and patient comfort.
2. Are there ongoing clinical trials to expand ioversol’s indications?
Yes. Current trials are focusing on pediatric applications, use in renal impairment, and neurovascular imaging, aiming to broaden usage profiles and regulatory approvals.
3. How does the regulatory landscape influence ioversol’s market growth?
Regulatory agencies favor low-osmolality, nonionic contrast media for their safety profiles, facilitating approvals in new markets. Conversely, delays or restrictions could hinder adoption; thus, compliance and robust safety data are vital.
4. What are the main competitive challenges for ioversol?
Intense competition from agents like iodixanol and iohexol, price sensitivity, and regulatory changes pose challenges. Differentiation based on safety, efficacy, and clinical data remains essential.
5. What is the outlook for ioversol in emerging markets?
The rapid expansion of diagnostic imaging infrastructure, combined with favorable regulatory reforms, positions ioversol for significant growth, provided supply chain and pricing strategies are optimized.
Key Takeaways
- Stable Clinical Development: Clinical trials support ioversol’s safety and efficacy, with ongoing studies aimed at expanding its indication spectrum.
- Market Growth Drivers: Increasing global imaging procedures, technological advances, and regulatory favorability underpin projected CAGR of 5.2% to 2030.
- Competitive Positioning: Ioversol’s low-osmolality profile is advantageous; differentiation strategies focus on safety and expanding pediatric/renal indications.
- Emerging Market Opportunities: Asia-Pacific and Latin America present high-growth avenues, contingent on regulatory and infrastructural developments.
- Strategic Focus: Innovative formulations, combination imaging protocols, and regulatory engagement will drive sustained market share growth.
References
[1] MarketsandMarkets. (2022). Contrast Media Market by Type, Application, Region - Global Forecast to 2025.
[2] Grand View Research. (2023). Iodinated Contrast Media Market Size, Share & Trends Analysis Report.
[3] GE Healthcare. (2021). Optiray Product Information.
[4] Bracco Diagnostics. (2022). Visipaque (iodixanol) Safety and Efficacy Data.
Note: All projections are estimates based on current market trends and data available as of Q1 2023.
